Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice

Eisai

Status: Completed

Conditions: Alzheimer's Disease

Treatments: Drug: Donepezil Hydrochloride

Study type: Observational

Funder types: Industry

Identifiers

NCT02162264

ART08T

Details and patient eligibility

About

To investigate the factors that affect Aricept medication persistence rate and the safety and efficacy in patients with Alzheimer's Disease in clinical practice

Enrollment: 8,662 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients diagnosed with Alzheimer's Disease and administered Aricept for the first time.

Exclusion criteria

Patients with a history of hypersensitivity to any ingredients of Aricept or piperidine derivatives.

Trial design

8,662 participants in 1 patient group

E2020

Treatment:

Drug: Donepezil Hydrochloride